Adding BP1001 to Venetoclax and Decitabine for Acute Myeloid Leukemia Treatment

Recruiting · Phase 2 · Acute Myeloid Leukemia (AML) · 7 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This study looks at how well BP1001 works with venetoclax and decitabine for patients with acute myeloid leukemia (AML) who cannot have more intense chemotherapy. Researchers want to see if this combination helps more patients reach complete remission than venetoclax and decitabine alone. The aim is to find new treatments for patients with AML, especially those who have not responded to other drugs.

The trial's ID number is NCT02781883. It is a Phase 2 trial, which means it is looking at how well the treatment works and how safe it is. The trial hopes to include about 108 participants.

Who can join

Adults aged 18 and older can join this trial. It is open to all genders. Participants must have a specific type of AML and be unable or unwilling to receive intensive chemotherapy. The trial team will confirm who is eligible to participate.

Condition

Acute Myeloid Leukemia (AML)

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants will receive treatment in one of three groups. One group will include untreated AML patients who will get BP1001 along with venetoclax and decitabine. The second group will involve patients with relapsed or refractory AML receiving the same combination. The third group will consist of patients who cannot tolerate venetoclax, who will get BP1001 and decitabine. All treatments are experimental, and participants will not be randomly assigned to groups.